Fosfomycin and nitrofurantoin: classic antibiotics and perspectives

Santos, Cristiane dos; Souza, Lucas Santos; Franco, Octávio Luiz

doi:10.1038/s41429-021-00444-z

Cited by 18 publications

(12 citation statements)

References 133 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…63 Fosfomycin is a low-molecular-weight phosphonic acid derivative that was first isolated from Streptomyces species. 64 Moreover, the physicochemical profile of fosfomycin, which has a low molecular weight (138 Da) and distinctive hydrophilic qualities along with a negligible affinity for plasma proteins, allows for a wide distribution into a variety of tissues. Furthermore, fosfomycin antibiotic exposed its antibacterial mode of action through interfering with the initial phases of peptidoglycan synthesis and thus disrupting the biosynthesis of bacterial cell walls.…”

Section: Screening Of the Antibacterial Potency Of The Biosynthesized...mentioning

confidence: 99%

Synergistic Antibacterial Potential of Greenly Synthesized Silver Nanoparticles with Fosfomycin Against Some Nosocomial Bacterial Pathogens

Aljeldah

Yassin

Mostafa

et al. 2023

IDR

View full text Add to dashboard Cite

Introduction A considerable number of morbidities and fatalities occur worldwide as a result of the multidrug resistant microorganisms that cause a high prevalence of nosocomial bacterial infections. Hence, the current investigation was conducted to evaluate the antibacterial potency of green fabricated silver nanoparticles (AgNPs) against four different nosocomial pathogens. Methods The flower extract of Hibiscus sabdariffa mediated green fabrication of AgNPs and their physicochemical features were scrutinized using different techniques. Antimicrobial activity of the biogenic AgNPs and their synergistic patterns with fosfomycin antibiotic were evaluated using disk diffusion assay. Results and Discussion UV spectral analysis affirmed the successful formation of AgNPs through the detection of broad absorption band at 395 and 524 nm, indicating the surface plasmon resonance of the biofabricated AgNPs. In this setting, the biofabricated AgNPs demonstrated average particle size of 58.682 nm according to transmission electron microscope (TEM) micrographs. The detected hydrodynamic diameter was higher than that noticed by TEM analysis, recording 72.30 nm in diameter and this could be attributed to the action of capping agents, which was confirmed by Fourier Transform Infrared (FT-IR) analysis. Disk diffusion assay indicated the antibacterial potency of biogenic AgNPs (50 μg/disk) against Enterobacter cloacae , Methicillin-resistant Staphylococcus aureus, Klebsiella pneumoniae and Escherichia coli strains with relative inhibition zone diameters of 12.82 ± 0.36 mm, 14.54 ± 0.15 mm, 18.35 ± 0.24 mm and 21.69 ± 0.12 mm, respectively. In addition, E. coli was found to be the most susceptible strain to the biogenic AgNPs. However, the highest synergistic pattern of AgNPs-fosfomycin combination was detected against K. pneumonia strain recording relative synergistic percentage of 64.22%. In conclusion, the detected synergistic efficiency of AgNPs and the antibiotic fosfomycin highlight the potential for utilizing this combination in the biofabrication of effective antibacterial agents against nosocomial pathogens.

show abstract

Section: Screening Of the Antibacterial Potency Of The Biosynthesized...mentioning

confidence: 99%

Synergistic Antibacterial Potential of Greenly Synthesized Silver Nanoparticles with Fosfomycin Against Some Nosocomial Bacterial Pathogens

Aljeldah

Yassin

Mostafa

et al. 2023

IDR

View full text Add to dashboard Cite

show abstract

“…To overcome the therapeutic limitations created by bacterial resistance, some strategies have been considered ( Vargas-Casanova et al, 2019 ). In addition to antibiotic combinations, which are a common practice in the hospital environment, antibiotic association with AMPs has been demonstrated as a potential resource against AMR agents ( dos Santos et al, 2021 ; Li et al, 2021 ). Recent reports can demonstrate the increased activity of the combination (AMP-antibiotic), revealing a potentialized effect.…”

Section: Clinically Significant Advances In Synergism Between Amp/ant...mentioning

confidence: 99%

Advances and perspectives for antimicrobial peptide and combinatory therapies

Santos

et al. 2022

Front. Bioeng. Biotechnol.

View full text Add to dashboard Cite

Antimicrobial peptides (AMPs) have shown cell membrane-directed mechanisms of action. This specificity can be effective against infectious agents that have acquired resistance to conventional drugs. The AMPs’ membrane-specificity and their great potential to combat resistant microbes has brought hope to the medical/therapeutic scene. The high death rate worldwide due to antimicrobial resistance (AMR) has pushed forward the search for new molecules and product developments, mainly antibiotics. In the current scenario, other strategies including the association of two or more drugs have contributed to the treatment of difficult-to-treat infectious diseases, above all, those caused by bacteria. In this context, the synergistic action of AMPs associated with current antibiotic therapy can bring important results for the production of new and effective drugs to overcome AMR. This review presents the advances obtained in the last 5 years in medical/antibiotic therapy, with the use of products based on AMPs, as well as perspectives on the potentialized effects of current drugs combined with AMPs for the treatment of bacterial infectious diseases.

show abstract

“…For uncomplicated cystitis caused by STEC, the main first-line empirical treatment is fosfomycin [ 16 ]. Fosfomycin is a broad-spectrum bactericidal antibiotic and among the most active agents used for sparing carbapenems in extended-spectrum b-lactamase (ESBL)-producing isolates and the treatment of carbapenem-resistant Enterobacteriaceae in combination with colistin [ 17 ].…”

Section: Introductionmentioning

confidence: 99%

Luteolin 4′-Neohesperidoside Inhibits Clinically Isolated Resistant Bacteria In Vitro and In Vivo

et al. 2023

View full text Add to dashboard Cite

Multidrug resistance (MDR) pathogens are usually associated with higher morbidity and mortality rates. Flavonoids are good candidates for the development of new potential antimicrobials. This research investigated whether luteolin 4′-neohesperidoside (L4N) has antibacterial and synergistic activities against four antibiotic-resistant pathogens: methicillin-resistant Staphylococcus aureus (MRSA), Klebsiella pneumoniae, fosA-positive shiga toxin producing the Escherichia coli serogroup O111 (STEC O111), and Bacillus cereus. In vitro antimicrobial susceptibility testing revealed highly potent anti-MRSA (MIC of 106.66 ± 6.95 µg/mL), anti-K. pneumoniae (MIC of 53.33 ± 8.47 µg/mL) and anti-STEC O111 (MIC of 26.66 ± 5.23 µg/mL) activities. Significant synergistic combination was clearly noted in the case of gentamycin (GEN) against Gram-negative bacteria. In the case of B. cereus, the combination of vancomycin (VAN) with L4N could efficiently inhibit bacterial growth, despite the pathogen being VAN-resistant (MIC of 213.33 ± 7.9 µg/mL). In vivo evaluation of L4N showed significant decreases in K. pneumoniae and STEC shedding and colonization. Treatment could significantly diminish the levels of pro-inflammatory markers, tumor necrosis factor-alpha (TNF-α), and immunoglobulin (IgM). Additionally, the renal and pulmonary lesions were remarkably enhanced, with a significant decrease in the bacterial loads in the tissues. Finally, this study presents L4N as a potent substitute for traditional antibiotics with anti-STEC O111 and anti-K. pneumoniae potential, a finding which is reported here for the first time.

show abstract

Fosfomycin and nitrofurantoin: classic antibiotics and perspectives

Cited by 18 publications

References 133 publications

Synergistic Antibacterial Potential of Greenly Synthesized Silver Nanoparticles with Fosfomycin Against Some Nosocomial Bacterial Pathogens

Synergistic Antibacterial Potential of Greenly Synthesized Silver Nanoparticles with Fosfomycin Against Some Nosocomial Bacterial Pathogens

Advances and perspectives for antimicrobial peptide and combinatory therapies

Luteolin 4′-Neohesperidoside Inhibits Clinically Isolated Resistant Bacteria In Vitro and In Vivo

Contact Info

Product

Resources

About